Effectiveness Report of T-AYU-HM Premium and Onion Vaporisation on Corona Positive Sickle Cell Anemia Patients: A Case Study
Abstract
Corona virus increases mortality in patients with comorbidities like diabetes, hypertension, cancer, haemoglobin disorders. The entry of corona virus in sickle cell anemia patients demands a personalised medical management strategy because till date standard cure is not available for both the illnesses. Coronavirus infection causes damage to alveoli leading to an impaired oxygen exchange which might result in sickling of red blood corpuscles inducing various complications in patients of sickle cell anemia. Management of sickle cell patients infected with coronavirus has presented with a challenge in the current situation. A case report discuss here is of 2 sickle cell anemia patients with positive Covid-19 test who came to the clinic seeking treatment. With prior consent, we advised T-AYU-HM Premium and Onion vaporisation treatment for 21 days. We observed remarkable clinical improvement in patients’ haemoglobin, RBC, ESR and CRP profiles during followed up visit. The formulation’s impact on red blood corpuscles helps in preventing vaso-occlusive crisis and thereby the requirement of hospitalisation. The patients’ clinical recovery observed without any use of supportive medications commonly required in patients of sickle cell and coronavirus infection. This case report study provides information on the role of an alternative system of medicine in comorbidities in patients infected with coronavirus across the country. This therapeutic approach might open a door for an economical, safe and effective management options for sickle cell anemia patients infected with coronavirus in future.
Keywords:
Sickle cell anemia, Corona virus infection, T-AYU-HM Premium, Onion VaporisationDOI
https://doi.org/10.25004/IJPSDR.2021.130115References
Zhou P, Yang X-L, Wang X-G, Hu B, Zhang L, Zhang W, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020; 579:270–273.
Guan W-J, Ni Z-Y, Hu Y, Liang W-H, Ou C-Q, He J-X, et al. Clinical characteristics of coronavirus disease 2019 in China. New Engl J Medicine. 2020; 382:1708-1720.
Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA. 2020; 323(11):1061-1069.
Yang X, Yu Y, Xu J, Shu H, Xia J, Liu H, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 Pneumonia in Wuhan, China: a single centered, retrospective, observational study. Lancet Respir Med. 2020; 8(5):475-481.
Desai AM, Saraf MN, Desai C, Desai H and Dalal M: Clinical evaluation of T-AYU-HMTM in the management of sickle cell anemia. Int J Pharm Sci& Res. 2018; 9(8): 3573-3578.
Beerkens, F, John, M, Puliafito, B, Corbett, V, Edwards, C & Tremblay, D. COVID‐19 pneumonia as a cause of acute chest syndrome in an adult sickle cell patient. Am J Hematol. 2020. 95(7):E154-E156.
De Luna G, Habibi A, Deux JF, Colard M, d'Alexandryd'Orengiani ALPH, Schlemmer F, et al. Rapid and severe Covid‐19 Pneumonia with severe acute chest syndrome in a sickle cell patient successfully treated with tocilizumab. Am J Hematol. 2020; 95(7):876-878.
Hussain FA, Njoku FU, Saraf SL, Molokie RE, Gordeuk VR, Han J. C OVID‐19 i nfection i n p atients w ith s ickle c ell d isease. B r J Haematol. 2020; 189(5):851-852.
McCloskey KA, Meenan J, Hall R, Tsitsikas DA. COVID‐19 infection and sickle cell disease: a UK Centre experience. Br J Haematol. 2020; 190(2):e57-e58.
Nur E, Gaartman AE, van Tuijn CFJ, Tang MW, Biemond BJ. Vaso‐occlusive crisis and acute chest syndrome in sickle cell disease due to 2019 novel Coronavirus Disease (COVID‐19). Am JHematol. 2020; 95(6):725-726.
Morera D, MacKenzie SA. Is there a direct role for erythrocytes in the immune response? Veterinary research. 2011; 42(1), 89.
We n z hon g L , Hu a l a n L . C OV I D -19 D i s e a s e : OR F 8 a n d surface glycoprotein inhibit heme metabolism by binding to porphyrin. ChemRxiv. 2020; Preprint. 10.26434/chemrxiv.11938173. v3.
Wenzhong L, Hualan L. COVID-19: Attacks the 1-beta chain of hemoglobin and captures the porphyrin to inhibit human heme met abolism. ChemR x iv. 2020; Preprint . 10.26434/ chemrxiv.11938173.v8.
Cavezzi A, Troiani E, Corrao S. COVID-19: hemoglobin, iron, and hypoxia beyond inflammation. A narrative review. Clinics and practice. 2020; 10(2), 1271.
Setty BN, Stuart MJ. Vascular cell adhesion molecule-1 is involved in mediating hypoxia-induced sickle red cell adherence to endothelium: potential role in sickle cell disease. Blood.1996; 88:2311–20.
Stuart MJ, Setty BNY. Acute chest syndrome of sickle cell disease: a new light on an old problem. CurrOpin Hematol.2001; 8: 111–122.
Stuart MJ, Setty BN. Sickle cell acute chest syndrome: pathogensis and rationale for treatment. Blood.1999; 94:1555–1560.
Desai C, Desai J, Desai S, Kajal K. A brief review on the management options available for sickle cell anemia: journal of pharmaceutical science and bioscientific research. 2015; 5(2): 230-238.
Desai AM, Desai C, Desai H, Mansuri A, Desai J. Possible Role of Medicinal Plants In Covid-19: A Brief Review, International Journal of Science & Engineering Development Research. 2020;5(4):205– 209.
Desai AM, Saraf MN, Desai C, Desai H, Dalal M. Clinical Evaluation of T-AYU-HM in the management of Sickle Cell Anemia. IJPSR. 2018; 9(8):3573-3578
Desai A, Desai H, Desai C, Desai R. Possible Role of T-AYU-HM Premium and Ot her Herbal Drug Treatment s In Cov id19, International Journal of Science & Engineering Development Research. 2020;5(4):272–274.
Guan W, Ni Z, Hu Y et al, Clinical characteristics of 2019 novel corona virus infection in China. medR xiv. 2020; 10.1101/ 2020.02.06.20020974
Tang N, Li D, Wang X, Sun Z, Abnormal coagulation parameters are associated with poor prognosis in patients with novel corona virus pneumonia. J Thromb Haemost. 2020; 18(4): 844–847.
Desai A, Desai K, Desai H, Desai C, Desai R. A Case Report on the Effects of Onion Steam Vapour/Nebulisation and T-AYU-HM Premium Tablets in Covid-19 Patient. J Pharm Sci Bioscientific Res. 2020; 10(2):171-174
Wastnedge, E., Waters, D., Patel, S., Morrison, K., Goh, M. Y., Adeloye, D., & Rudan, I. The global burden of sickle cell disease in children under five years of age: a systematic review and meta-analysis. Journal of global health. 2018; 8(2), 021103.
Coronavirus (COVID‐19) & Sickle Cell Disorder. n.d. Retrieved May 18, 2020, from https://www.sicklecellsociety.org/coronavirus‐and‐scd/.
Steinberg MH. Management of sickle cell disease. N Engl J Med. 1999; 340(13):1021–1030.
Inusa B, Zuckerman M, Gadong N, Afif M, Arnott S, Heath P, et al. Pandemic influenza A (H1N1) virus infections in children with sickle cell disease. Blood. 2010; 18; 115(11):2329-2330.
Sahu KK, Siddiqui AD, jen cerny. Managing sickle cell patients with Covid-19 infection: the need to pool our collective experience; British Journal of Haematology.2020; 190, e57-e94.
Published
Abstract Display: 621 
PDF Downloads: 538 
